Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments.

Vertex Advances on VX-950

August 19, 2005

Printer-friendly version

Bookmark and Share

Vertex has really been getting a positive roll on its clinical studies for VX-950 so far. It may be the first of a new generation of Hepatitis c therapies to hit the market, and that has investors very excited. Not to mention patients.

Vertex hits new 52-week high on upgrade

AUG. 19 11:43 A.M. ET

Shares of Vertex Pharmaceuticals Inc. jumped over 15 percent and set a new 52-week high Friday following an upgrade from investment firm JPMorgan over growing confidence for its early stage experimental hepatitis C treatment.

Vertex shares rose $2.60, or 15.9 percent, to $18.97, surpassing a former 52-week high of $18.14, in morning trading on the Nasdaq. Its stock has climbed from a 52-week low of $8.61 in April and surged in May as Vertex began releasing data from its early stage hepatitis C clinical trial. Company shares are up nearly 80 percent on the year.

JPMorgan upgraded Vertex to "Overweight" from "Neutral" in anticipation of additional safety data on the company's hepatitis C treatment VX-950 in the second half of 2005 and the initiation of mid-stage clinical trials for the drug.

Analyst Richard Smith said he believes favorable results will be replicated in upcoming mid-stage trials, and said VX-950 could potentially reduce treatment times of hard-to-treat patients. In May, the company released data showing that VX-950 decreased levels of hepatitis C genetic material within 14 days and was well-tolerated by the 34 patients enrolled in the study. "Our upgrade to Overweight is based on our increased conviction that VX-950 will be a successful product and that it represents a blockbuster opportunity for the company and the rest of the pipeline represents merely further upside if successful," Smith told investors in a research note.

The analyst also presented comparative data in his note showing that VX-950 caused the largest reduction of hepatitis C genetic material in patients out of a class of nine other experimental treatments being developed by other companies. Smith estimates the hepatitis C treatment market is heating up and may reach more than $8 billion in 2010.

Smith maintained his forecast of a loss per share of $1.86 for 2005, and improved his 2006 projection to a loss of $1.89 from a loss of $1.92. Analysts surveyed by Thomson Financial expect the company to post a loss per share of $1.76 in 2005 and $1.75 in 2006.

Posted by Ralph at August 19, 2005 5:29 AM

Site Topics

  • HCV Symptoms

    You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.

  • Lab Tests

    What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.

  • Hepatitis C Genotypes

    Learn about Hepatitis C Genotypes and their variants.

  • Viral Load

    Includes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.

  • What is...?

    Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.

  • HCV Medicines

    Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.

  • Hepatitis C Doctors

    A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.

  • Biopsy Info

    A comprehensive resource of information relating to the liver biopsy.

  • Cirrhosis

    Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.

  • Liver Cancer

    Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.

  • Liver Disease Medicines

    An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.

  • Hep-Central Email List

    Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.

  • HCV Links

    Convenient links to other sites external to Hepatitis-Central.

  • Mother/Child Transmission

    Discussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.

  • HCV Natural Remedies

    A number of herbal products useful in the management of liver disease.

  • HCV Books

    Recommended reading for those interested in hepatitis information.

  • Hepatitis C Forum

    A Bulletin Board for discussions on hepatitis, treatments, etc.

  • Hepatitis C Activism

    An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.

Advertisement

Search R&T News

Advertisement